1-5 of 5
Leonard Post
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma

Available to Purchase
Xiaocheng Chen, Oi Kwan Wong, Lauren Reiman, Daniel W. Sherbenou, Leonard Post
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (2): 127–138.
https://doi.org/10.1158/1535-7163.MCT-23-0052
Published: 01 February 2024
View article titled, CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma
Open the PDF for CD38 x ICAM-1 Bispecific Antibody Is a Novel Approach for Treating Multiple Myeloma and Lymphoma in another window
Includes: Supplementary data
Journal Articles

Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K/AKT/mTOR pathways

Free
Tracy T Tang, Leonard Post
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2023) 22 (12_Supplement): B088.
https://doi.org/10.1158/1535-7163.TARG-23-B088
Published: 01 December 2023
View article titled, Abstract B088: VT3989, the first-in-class and first-in-human TEAD auto-palmitoylation inhibitor, enhances the efficacy and durability of multiple targeted therapies of the MAPK and P13K/AKT/mTOR pathways
Journal Articles

Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma

Available to Purchase
Tracy T. Tang, Andrei W. Konradi, Ying Feng, Xiao Peng, Mingyue Ma, Jian Li, Fa-Xing Yu, Kun-Liang Guan, Leonard Post
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2021) 20 (6): 986–998.
https://doi.org/10.1158/1535-7163.MCT-20-0717
Published: 01 June 2021
View article titled, Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma
Open the PDF for Small Molecule Inhibitors of TEAD Auto-palmitoylation Selectively Inhibit Proliferation and Tumor Growth of NF2-deficient Mesothelioma in another window
Includes: Supplementary data
Journal Articles

Abstract B93: Preclinical evaluation of BMN 673 in combination with temozolomide (TMZ) in various tumor types including small cell lung cancer (SCLC) cells.

Free
Ying Feng, Leonard Post, Bing Wang, Yuqiao Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B93.
https://doi.org/10.1158/1535-7163.TARG-13-B93
Published: 01 November 2013
View article titled, Abstract B93: Preclinical evaluation of BMN 673 in combination with temozolomide (TMZ) in various tumor types including small cell lung cancer (SCLC) cells.
Journal Articles

Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies

Free
Bing Wang, Daniel Chu, Ying Feng, Xin Yu, Peter Myers, Leonard Post, Yuqiao (Jerry) Shen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A121.
https://doi.org/10.1158/1535-7163.TARG-09-A121
Published: 10 December 2009
View article titled, Abstract A121: Novel PARP inhibitors with potent antitumor activity as single‐agent and combination therapies